S
Symphogen
Develops antibodies for cancer treatments
About Symphogen
Symphogen was founded in 2000 by Kirsten Drejer, a visionary in the field of biotechnology. The company, based in Ballerup, Denmark, set out with a mission to develop innovative recombinant antibody therapies aimed at treating cancer and other serious diseases. Symphogen's approach was unique, focusing on creating mixtures of monoclonal antibodies to enhance treatment efficacy and patient outcomes.
Read full description
Over the years, Symphogen made significant strides in the biopharmaceutical industry, advancing its pipeline of antibody therapies through rigorous research and development. The company's dedication to innovation and patient care positioned it as a leader in the field of oncology-focused antibody treatments.
A pivotal moment in Symphogen's journey came in June 2020, when it became part of the Servier Group, a global pharmaceutical company. This acquisition was a strategic move to bolster Servier's oncology research and development capabilities, aligning with their commitment to improving patient health worldwide. The integration into Servier provided Symphogen with additional resources and support to further its mission of developing cutting-edge therapies.
Today, Symphogen continues to operate as a key player within the Servier Group, driving forward its research in antibody therapies. The company's story is one of innovation, resilience, and a steadfast commitment to transforming the landscape of cancer treatment through scientific excellence.
At a glance
- Founded
- 2000
- Headquarters
- Ballerup, Denmark
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Madison Alley Global Ventures
Series B and later5 investors entered at this stage
Essex Woodlands Health Ventures
Novo Holdings
Gilde Healthcare
Takeda Ventures
EW Healthcare Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Symphogen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Symphogen on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.